Cigna Group 경영진
경영진 기준 점검 3/4
Cigna Group CEO는 David Cordani, Dec2009 에 임명되었습니다 의 임기는 16.42 년입니다. 총 연간 보상은 $22.87M, 7% 급여 및 93% 보너스(회사 주식 및 옵션 포함)로 구성됩니다. 는 $184.87M 가치에 해당하는 회사 주식의 0.25% 직접 소유합니다. 경영진과 이사회의 평균 재임 기간은 2.1 년과 6.7 년입니다.
핵심 정보
David Cordani
최고경영자
US$22.9m
총 보수
| CEO 급여 비율 | 7.00% |
| CEO 재임 기간 | 16.4yrs |
| CEO 지분 보유율 | 0.2% |
| 경영진 평균 재임 기간 | 2.1yrs |
| 이사회 평균 재임 기간 | 6.7yrs |
최근 경영진 업데이트
Recent updates
Seeking Alpha • May 18
Cigna: Shares Marching To Full Recovery
Summary Cigna Group is reiterated as a "Buy," driven by strong Q1 2026 results, raised guidance, and sustained business momentum. CI’s pharmacy and behavioral health segments are fueling revenue growth, while divestitures and PBM reform temporarily temper 2026 earnings. Shares trade at a 25% discount to a $377 fair value estimate, offering potential 15% annual total returns through 2031. Cigna’s robust balance sheet, market-leading dividend coverage, and growth catalysts in biosimilars and behavioral health underpin the investment thesis. Read the full article on Seeking Alpha분석 기사 • May 04
The The Cigna Group (NYSE:CI) First-Quarter Results Are Out And Analysts Have Published New Forecasts
The Cigna Group ( NYSE:CI ) came out with its first-quarter results last week, and we wanted to see how the business is...
내러티브 업데이트 • May 02
CI: Leadership Transition And Buybacks Will Support Future Share Upside
Analysts have increased their price target on Cigna Group by about $1. This reflects small adjustments to fair value, discount rate, revenue growth, profit margin, and future P/E assumptions in their models.내러티브 업데이트 • Apr 17
CI: Leadership Transition And Buybacks Will Drive Future Upside
Analysts have trimmed their average price target on Cigna Group by about $0.38 to roughly $338.42, reflecting small updates to fair value estimates, discount rate, revenue growth, profit margin, and future P/E assumptions. What's in the News The Cigna Group plans a leadership transition, with current CEO David M.내러티브 업데이트 • Apr 02
CI: Leadership Transition And Onsite Care Expansion Will Drive Future Upside
Analysts have slightly refined their view on Cigna Group, trimming the price target by a fraction to $338.79 as updated assumptions for revenue growth, profit margins, and future P/E bring the model into closer alignment with their latest expectations. What's in the News Cigna Group plans a leadership transition, with David M.내러티브 업데이트 • Mar 19
CI: Onsite Care Expansion And Leadership Transition Will Support Future Upside
Analysts have nudged their fair value estimate for Cigna Group from about $336.67 to roughly $338.80. This reflects updated views on revenue growth, profit margins, and an anticipated forward P/E of around 13.43x.내러티브 업데이트 • Mar 05
CI: Onsite Care Expansion Will Support Future Upside Potential
Analysts now set Cigna Group's fair value estimate at about $336.67, up from roughly $332.62, reflecting updated assumptions that incorporate slightly higher revenue growth, profit margins, and a lower future P/E multiple. What's in the News Cigna Group plans a leadership transition, with CEO David M.내러티브 업데이트 • Feb 19
CI: Higher Margin Outlook And Onsite Care Expansion Will Support Upside
Analysts have modestly lifted their price target on Cigna Group to $332.62 from $326.92, citing updated assumptions that combine slightly lower revenue growth with a higher profit margin and a future P/E of 15.62. What's in the News A class action lawsuit has been filed against Express Scripts, Cigna, and Evernorth, alleging a rebate diversion scheme that used an offshore entity, Ascent, to collect billions of dollars in kickbacks labeled as fees instead of passing rebates through to pharmacy benefit management clients, including the Plumbers' Welfare Fund.내러티브 업데이트 • Feb 04
CI: Onsite Clinic And Stable Assumptions Will Support Future Upside
Analysts have kept their price target for The Cigna Group broadly unchanged at about US$327, citing only slight adjustments to revenue growth, profit margin and future P/E assumptions rather than any major shift in their outlook. What's in the News Hankook Tire America Corp.내러티브 업데이트 • Jan 21
CI: Completed Buybacks And New Employee Clinic Will Support Future Upside
Analysts have nudged their fair value estimate for Cigna Group slightly higher to US$326.92 from US$325.57, citing minor refinements to discount rate assumptions, revenue growth expectations, profit margin inputs, and the forward P/E multiple used in their models. What's in the News Hankook Tire America Corp.내러티브 업데이트 • Jan 07
CI: Massive Share Buyback And Clinic Expansion Will Support Future Earnings Upside
Analysts have slightly reduced their price target for Cigna Group, trimming fair value by about $0.69 to $325.57 as they factor in a more moderate revenue growth outlook, along with a small improvement in expected profit margins and future P/E assumptions. What's in the News Hankook Tire America Corp.내러티브 업데이트 • Dec 15
CI: Massive Share Buyback Will Drive Future Earnings Upside Momentum
Narrative Update on Cigna Group Analysts have slightly lowered their price target on Cigna Group by approximately $2 to around $326 per share, reflecting modest tweaks to assumptions on long term growth, profitability, and valuation multiples, while maintaining a broadly constructive outlook. What's in the News Cigna Group reported that between July 1 and September 30, 2025, it repurchased no additional shares under its existing authorization, having already completed the buyback of about 133.5 million shares, or 41.09% of shares outstanding, for roughly $34.44 billion since the program was announced in December 2018 (company filing).내러티브 업데이트 • Nov 30
CI: Massive Share Buyback Will Drive Future Earnings Upside Momentum
Analysts have raised their price target for Cigna Group to $328.35 per share, citing moderate adjustments to key financial metrics. These include a higher projected future price-to-earnings ratio and continued expectations for growth and profitability.내러티브 업데이트 • Nov 16
CI: Significant Buybacks And 2026 Guidance Will Drive Upside Momentum
Narrative Update on Cigna Group Analysts have lowered their price target for Cigna Group from $349.04 to $328.35. This change reflects adjustments for a slightly higher discount rate as well as revised expectations for revenue growth and profit margins.내러티브 업데이트 • Nov 01
CI: Share Repurchase Momentum Will Drive Long-Term Shareholder Value Creation
Analysts have lowered their price target for Cigna Group from $369.13 to $349.04. This change reflects updated expectations around modestly higher revenue growth, which are offset by a slight dip in profit margin projections.분석 기사 • Jul 10
The Cigna Group (NYSE:CI) Screens Well But There Might Be A Catch
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") above 19x, you may...분석 기사 • Jun 19
These 4 Measures Indicate That Cigna Group (NYSE:CI) Is Using Debt Reasonably Well
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Seeking Alpha • Mar 31
The Cigna Group: Compelling Exposure To Diversified Healthcare At A Discount Price
Summary Cigna is positioned to benefit from utilization normalization and aims for 10%-14% annual EPS growth by reducing Medicare exposure and improving Commercial business. Despite industry challenges, Cigna achieved 8%-9% YoY EPS growth in 2023-2024, demonstrating strong cost discipline and effective management. The sale of Cigna's Medicare unit and focus on lower-cost biosimilars and streamlined care accessibility are key strategic moves for future growth. With an attractive valuation and minimal downside risk, Cigna stock is rated a BUY, offering at least 33% upside potential even in bearish conditions. Read the full article on Seeking AlphaSeeking Alpha • Feb 17
Cigna Is A Buy: Market Overreaction Creates A Big Opportunity
Summary Cigna looks undervalued at under 10x earnings, with strong growth potential. Evernorth continues to expand, adding to the company’s long-term value. Large stock buybacks are supporting earnings per share and investor returns. Regulatory risks, rising costs, and competition remain challenges to watch. If Cigna meets its targets, the stock could rise 20-30% from here. Read the full article on Seeking AlphaSeeking Alpha • Jan 18
Cigna: Buy The Drop On This Undervalued Growth Stock
Summary Cigna's current valuation presents a compelling opportunity, trading at a forward PE of 9.9, significantly below its historical average of 12.0x. The company carries diversified revenue streams and consistent earnings growth, with Healthcare and Evernorth divisions driving strong performance and a 13% EPS CAGR over 10 years. Management targets 10-14% long-term annual EPS growth, supported by increased biosimilar adoption, behavioral health services growth, and aggressive share buybacks. CI's growing dividend and robust fundamentals make it an attractive choice for value and growth investors, despite potential regulatory and macroeconomic risks. Read the full article on Seeking AlphaSeeking Alpha • Dec 13
Cigna And The Risk Of PBMs - I'm Staying Out Above $230/Share
Summary Cigna faces significant risks due to potential healthcare reforms and scrutiny on PBMs, making it a "Hold" until it drops below $230/share. The US healthcare system's high costs and structural issues contribute to the uncertainty surrounding Cigna's long-term profitability and business model. Despite strong historical performance, the potential breakup of PBMs and legislative changes could drastically impact Cigna's future earnings and growth. The current valuation does not justify investment; Cigna's appeal lies in its fundamental strengths but is overshadowed by systemic risks and political uncertainties. Read the full article on Seeking AlphaSeeking Alpha • Sep 26
Cigna: This Dividend Grower Could Be Worth Buying Now
Summary The managed care company's total revenue and non-GAAP EPS climbed higher in the second quarter. Cigna's dividend is comfortably covered by non-GAAP EPS and free cash flow. Shares of the stock appear to be priced at a 17% discount to fair value. Cigna could be set up to generate strong total returns in the next couple of years. Read the full article on Seeking AlphaSeeking Alpha • Sep 19
Cigna: Growth From Specialty Pharmacy And Care; Initiate With 'Buy'
Summary I am initiating a 'Buy' rating for Cigna with a one-year target price of $450 per share, driven by strong Specialty and Cigna Healthcare growth. Cigna's Specialty Pharmacy and Care Market, accounting for 30% of revenue, is poised for above-market growth due to its leadership in the chronic market and biosimilar offerings. Cigna Healthcare's divestiture of low-margin Medicare businesses will allow focus on employer-sponsored plans, targeting small and mid-size enterprises, contributing to 7% organic revenue growth. Despite low operating margins and elevated cost trends, Cigna's share repurchase program and SG&A optimization are expected to support future margin expansion and free cash flow growth. Read the full article on Seeking AlphaSeeking Alpha • Jul 29
Cigna Group: Services Focus Leads To Outperformance
Summary Cigna Group's medical memberships are focused on "services-only" commercial memberships. The fee-based rather than risk-based nature of these memberships makes Cigna more resilient to rising medical costs. The Evernorth segment should see high-single-digit growth for the foreseeable future, driven by Healthcare Services and specialty pharmacy Accredo. The low valuation coupled with the mid-single-digit earnings growth outlook makes Cigna stock attractive at current prices. Read the full article on Seeking AlphaSeeking Alpha • Jul 12
Cigna: Game Over For PBMs?
Summary Pharmacy Benefit Managers are increasingly in the spotlight of regulators and the media, potentially leading to government intervention. Express Scripts, Cigna's PBM, is responsible for nearly 75% of the company's revenue, which raises the question of whether CI stock is still a safe investment. This article discusses the potential implications in a scenario-based approach, focusing on segment profit, consolidated profit, dividend safety, and valuation. In addition, I share my thoughts on the recent opioid litigation in Arkansas and explain why I continue to sleep well with my investment in Cigna. Read the full article on Seeking AlphaCEO 보수 분석
| 날짜 | 총 보수 | 급여 | 회사 수익 |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | US$6b |
| Dec 31 2025 | US$23m | US$2m | US$6b |
| Sep 30 2025 | n/a | n/a | US$6b |
| Jun 30 2025 | n/a | n/a | US$5b |
| Mar 31 2025 | n/a | n/a | US$5b |
| Dec 31 2024 | US$23m | US$2m | US$3b |
| Sep 30 2024 | n/a | n/a | US$3b |
| Jun 30 2024 | n/a | n/a | US$4b |
| Mar 31 2024 | n/a | n/a | US$4b |
| Dec 31 2023 | US$21m | US$2m | US$5b |
| Sep 30 2023 | n/a | n/a | US$5b |
| Jun 30 2023 | n/a | n/a | US$7b |
| Mar 31 2023 | n/a | n/a | US$7b |
| Dec 31 2022 | US$21m | US$2m | US$7b |
| Sep 30 2022 | n/a | n/a | US$7b |
| Jun 30 2022 | n/a | n/a | US$5b |
| Mar 31 2022 | n/a | n/a | US$5b |
| Dec 31 2021 | US$20m | US$2m | US$5b |
| Sep 30 2021 | n/a | n/a | US$8b |
| Jun 30 2021 | n/a | n/a | US$8b |
| Mar 31 2021 | n/a | n/a | US$8b |
| Dec 31 2020 | US$20m | US$2m | US$8b |
| Sep 30 2020 | n/a | n/a | US$5b |
| Jun 30 2020 | n/a | n/a | US$5b |
| Mar 31 2020 | n/a | n/a | US$5b |
| Dec 31 2019 | US$19m | US$2m | US$5b |
보상 대 시장: David의 총 보수(USD22.87M)는 US 시장에서 비슷한 규모 기업의 평균(USD14.81M)보다 높습니다.
보상과 수익: David의 보상은 지난 1년 동안 회사 실적과 일치했습니다.
CEO
David Cordani (60 yo)
16.4yrs
재임 기간
US$22,866,134
보수
Mr. David Michael Cordani serves as Chair of the Board at The Cigna Group (formerly known as Cigna Corporation) since January 01, 2022. He has been the Chief Executive Officer of The Cigna Group (formerly...
리더십 팀
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| CEO & Chair of the Board | 16.4yrs | US$22.87m | 0.25% $ 184.9m | |
| President | 1.2yrs | US$10.00m | 0.024% $ 18.1m | |
| Executive VP & CFO | 1.2yrs | US$4.69m | 0.0029% $ 2.2m | |
| Executive Vice President | 2.7yrs | US$5.96m | 0.013% $ 9.6m | |
| Executive Vice President of Strategy & Business Development | 2.3yrs | US$4.07m | 0.0021% $ 1.6m | |
| Senior VP & Tax and Global Chief Accounting Officer | 1.8yrs | 데이터 없음 | 0.00090% $ 668.6k | |
| Executive Vice President & Global Chief Information Officer | less than a year | 데이터 없음 | 0.0027% $ 2.0m | |
| Senior Vice President of Investor Relations | 4.3yrs | 데이터 없음 | 데이터 없음 | |
| EVP, General Counsel & Corporate Secretary | less than a year | 데이터 없음 | 데이터 없음 | |
| Executive Vice President | less than a year | 데이터 없음 | 데이터 없음 | |
| President of International MArkets & President of International Health Cigna Healthcare | 11.9yrs | US$3.53m | 데이터 없음 | |
| Head of Strategy & Global Business Development for Cigna International Markets | 6.2yrs | 데이터 없음 | 데이터 없음 |
2.1yrs
평균 재임 기간
54yo
평균 나이
경험이 풍부한 관리: CI의 경영진은 경험이 있음으로 간주됩니다(평균 재임 2.1 년).
이사회 구성원
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| CEO & Chair of the Board | 16.6yrs | US$22.87m | 0.25% $ 184.9m | |
| President | less than a year | US$10.00m | 0.024% $ 18.1m | |
| Independent Director | 21.3yrs | US$362.81k | 0.00073% $ 542.3k | |
| Lead Independent Director | 14.8yrs | US$360.31k | 0.014% $ 10.3m | |
| Independent Director | 19.1yrs | US$410.31k | 0.0018% $ 1.3m | |
| Independent Director | 5.9yrs | US$362.81k | 0.0020% $ 1.5m | |
| Independent Director | 7.4yrs | US$360.31k | 0.0026% $ 1.9m | |
| Independent Director | less than a year | US$239.47k | 0.00051% $ 378.9k | |
| Independent Director | 7.4yrs | US$335.31k | 0.0026% $ 1.9m | |
| Independent Director | 2.9yrs | US$335.31k | 0.00098% $ 728.0k | |
| Independent Director | 5.2yrs | US$335.31k | 0.0017% $ 1.3m | |
| Independent Director | 4.7yrs | US$337.81k | 0.0016% $ 1.2m |
6.7yrs
평균 재임 기간
61.5yo
평균 나이
경험이 풍부한 이사회: CI의 이사회는 경험이 있음으로 간주됩니다(평균 재임 6.7 년).
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/27 12:38 |
| 종가 | 2026/05/27 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
The Cigna Group는 40명의 분석가가 다루고 있습니다. 이 중 17명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| null null | Argus Research Company |
| Hua Ha | Baird |
| Joshua Raskin | Barclays |